Impact of Hepatic Steatosis on the Antiviral Effects of PEG-IFNα-2a in Patients with Chronic Hepatitis B and the Associated Mechanism

Table 4

Multivariate analysis of clinical parameters independently associated with significant histological abnormalities.

Patient characteristics	Clinical parameters	OR (95% CI)	value
Presence of hepatic steatosis		5.481 (2.992-10.041)	0.001
Presence of significant hepatic steatosis (≥S2)	Baseline AST	0.978 (0.959-0.998)	0.029
	Baseline UA	1.006 (1.000-1.012)	0.040
Presence of significant fibrosis (≥F2)	Baseline AST	1.006 (1.000-1.012)	0.038